Skip to Main Content

Paper Details

Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial.
Eur Heart J
104
2020
ACS, Alirocumab, LDL-C, Lipoprotein(a), acute coronary syndrome, alirocumab, cardiovascular, cardiovascular death, cholesterol, heart failure, lipoprotein(, lipoprotein(a, lipoprotein(a), low-density lipoprotein cholesterol, non-fatal myocardial infarction, patients, peripheral artery disease, stroke, subtilisin/kexin type 9, unstable angina, venous thromboembolism
Author NameAffiliation
Deepak L BhattBrigham and Women's Hospital Heart and Vascular Center, Harvard Medical School
Robert A HarringtonStanford Center for Clinical Research, Stanford University
Sotirios TsimikasUniversity of California San Diego, 9434 Medical Center Dr
  • 1 - 3

Datasets

Release 1.2